Khouri, I., Curbelo, F., Turturro, F., Jabbour, E., Milton, D., RL, B. , Jr, … Sharma, P. (2018). Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(5), 1011-1018. https://doi.org/10.1158/1078-0432.CCR-17-2777 (Original work published 2018)

, Spencer, C., Nezi, L., Reuben, A., Andrews, M., Karpinets, T., … Wargo, J. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)

Reuben, A., Gittelman, R., Gao, J., Zhang, J., Yusko, E., Wu, C., … Zhang, J. (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 7(10), 1088-1097. https://doi.org/10.1158/2159-8290.CD-17-0256

Gao, J., Ward, J., Pettaway, C., Shi, L., Subudhi, S., Vence, L., … Sharma, P. (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308

Haymaker, C., Kim, D., Uemura, M., Vence, L., Phillip, A., McQuail, N., … Diab, A. (2017). Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 5(2), 100-105. https://doi.org/10.1158/2326-6066.CIR-16-0223